Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 4/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6310438 | 0.85 | KDM1A (0.41) | HCRTR2HDAC4HDAC6TAS1R3TAS1R1 | |
| SCHEMBL5747737 | 0.78 | KDM1A (0.43) | KDM1A | |
| SCHEMBL3162419 | 0.77 | BTK (0.39) | TACR1NTRK1KDM1ANPY5ROPRL1 | |
| SCHEMBL3162428 | 0.77 | BTK (0.39) | TACR1NTRK1KDM1ANPY5ROPRL1 | |
| SCHEMBL3162412 | 0.77 | BTK (0.39) | TACR1NTRK1KDM1ANPY5ROPRL1 | |
| SCHEMBL6311266 | 0.76 | KDM1A (0.51) | TACR1KDM1A | |
| SCHEMBL5744386 | 0.76 | KDM1A (0.51) | TACR1KDM1A | |
| SCHEMBL5745869 | 0.76 | KDM1A (0.51) | TACR1KDM1A | |
| SCHEMBL5744384 | 0.76 | KDM1A (0.51) | TACR1KDM1A | |
| SCHEMBL5744393 | 0.76 | KDM1A (0.51) | TACR1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | F2R 289/4885TACR1 2/4885NTRK1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.